City of Hope | Strategic Alliance Partners

January 12, 2023

Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.

January 12, 2023

because of the differences between the characteristics of research subjects and individuals routinely cared for outside the confines of a clinical trial, appropriately designed examinations of “real-world” populations may provide a more relevant picture of the actual influence of a particular therapeutic intervention.

January 10, 2023

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

January 10, 2023

Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.

January 05, 2023

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

January 05, 2023

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

January 04, 2023

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

December 21, 2022

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

December 11, 2022

The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.

December 11, 2022

Tycel Phillips, MD, MPH, discusses the investigation of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma.

December 06, 2022

Chemotherapy prior to treatment with endocrine therapy could increase the risk of cancer-related cognitive impairment compared with endocrine therapy alone in women with breast cancer, irrespective of menopausal status.

November 29, 2022

Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.

November 22, 2022

Murali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.

November 14, 2022

A core component of any type of therapeutic research is to enhance clinical benefit.

November 14, 2022

With no approved agents for patients with malignant tumors harboring TSC1 or TSC2 inactivating alterations, investigators seek to establish a new pathway forward for patients with solid tumors in the PRECISION 1 trial.

October 31, 2022

Irene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.

October 26, 2022

One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.

October 20, 2022

Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.

October 20, 2022

Targeted treatment options for patients with HER2-mutant non–small cell lung cancer have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic.

October 14, 2022

What is noteworthy is the process whereby this patient employs both objective data and his personal beliefs to declare what he values.